Panelists Adam M. Brufsky, MD, PhD; Denise A. Yardley, MD; Carlos L. Arteaga, MD; José Baselga, MD, PhD; Kimberly L. Blackwell, MD; and Debu Tripathy, MD, discuss the data from the MONALEESA-2 trial, where ribociclib and letrozole as initial therapy in patients with HR-positive, HER2-negative advanced breast cancer improved progression-free survival over letrozole plus placebo.
